Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Captopril vs MitoQ: MitoQ has the stronger overall evidence (5 vs 3.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
MitoQ wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Captopril and MitoQ have evidence — compare verdict strength side-by-side.
Off-label longevity use mirrors low antihypertensive dosing (captopril is short-acting; longer-acting ACE inhibitors like lisinopril/ramipril are often used) under a clinician. Not an approved longevity regimen; blood pressure and potassium should be monitored. (the cited human trial does not state its captopril dose)
Any time of day
Oral tablet (or a longer-acting ACE inhibitor)
10-20mg daily
Morning
Oral capsule (mitoquinol mesylate, 10-20 mg)
Unknown in humans
Months to years
Years
Throughout use
Acute to 6 weeks
4 weeks
12 months
3 weeks
Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.
PLoS genetics (2016) · Animal
ACE inhibition extended lifespan in the worm C. elegans
The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging.
Development (Cambridge, England) (2024) · Animal
Captopril specifically inhibits the worm ACE homolog ACN-1
Control of aging by the renin-angiotensin system: a review of C. elegans, Drosophila, and mammals.
Frontiers in pharmacology (2022) · Review
Review framing RAS/ACE modulation as a conserved aging pathway
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.
Hypertension (Dallas, Tex. : 1979) (2018) · Rct · n=20
Randomized, placebo-controlled, double-blind crossover trial in 20 healthy older adults (60-79 yr) with impaired endothelial function
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society (2010) · Rct · n=128
PROTECT: multicenter double-blind RCT of 128 newly diagnosed, untreated Parkinson's patients over 12 months
The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients.
Liver international : official journal of the International Association for the Study of the Liver (2010) · Rct · n=30
Phase-II RCT: 30 chronic hepatitis-C patients randomized to mitoquinone (40 or 80 mg) or placebo once daily for 28 days
MitoQ has a higher evidence score (5/10 vs 3.5/10) and wins in 2 of 3 categories.
For support heart health, Captopril has a higher relevance score (62 vs 60).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.